185 related articles for article (PubMed ID: 30409442)
41. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
Fitzgerald DA; Hilton J; Jepson B; Smith L
Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
[TBL] [Abstract][Full Text] [Related]
42. Effects of guaifenesin, N-acetylcysteine, and ambroxol on MUC5AC and mucociliary transport in primary differentiated human tracheal-bronchial cells.
Seagrave J; Albrecht HH; Hill DB; Rogers DF; Solomon G
Respir Res; 2012 Oct; 13(1):98. PubMed ID: 23113953
[TBL] [Abstract][Full Text] [Related]
43. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy.
Gillissen A; Nowak D
Respir Med; 1998 Apr; 92(4):609-23. PubMed ID: 9659525
[TBL] [Abstract][Full Text] [Related]
44. Effects of drugs on mucus clearance.
Houtmeyers E; Gosselink R; Gayan-Ramirez G; Decramer M
Eur Respir J; 1999 Aug; 14(2):452-67. PubMed ID: 10515429
[TBL] [Abstract][Full Text] [Related]
45. Mucoactive agents for airway mucus hypersecretory diseases.
Rogers DF
Respir Care; 2007 Sep; 52(9):1176-93; discussion 1193-7. PubMed ID: 17716385
[TBL] [Abstract][Full Text] [Related]
46. Dornase alfa for cystic fibrosis.
Jones AP; Wallis C
Cochrane Database Syst Rev; 2010 Mar; (3):CD001127. PubMed ID: 20238314
[TBL] [Abstract][Full Text] [Related]
47. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
Geller DE
Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
[TBL] [Abstract][Full Text] [Related]
48. Dornase alfa as postoperative therapy in cystic fibrosis sinonasal disease.
Cimmino M; Nardone M; Cavaliere M; Plantulli A; Sepe A; Esposito V; Mazzarella G; Raia V
Arch Otolaryngol Head Neck Surg; 2005 Dec; 131(12):1097-101. PubMed ID: 16365224
[TBL] [Abstract][Full Text] [Related]
49. Inhalation of ambroxol inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway.
Ge LT; Liu YN; Lin XX; Shen HJ; Jia YL; Dong XW; Sun Y; Xie QM
Int Immunopharmacol; 2016 Apr; 33():90-8. PubMed ID: 26881857
[TBL] [Abstract][Full Text] [Related]
50. Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.
Wills PJ; Wodehouse T; Corkery K; Mallon K; Wilson R; Cole PJ
Am J Respir Crit Care Med; 1996 Aug; 154(2 Pt 1):413-7. PubMed ID: 8756815
[TBL] [Abstract][Full Text] [Related]
51. Mucus-controlling agents: past and present.
King M; Rubin BK
Respir Care Clin N Am; 1999 Dec; 5(4):575-94. PubMed ID: 10565882
[TBL] [Abstract][Full Text] [Related]
52. Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial.
Bishop JR; Erskine OJ; Middleton PG
J Physiother; 2011; 57(4):223-9. PubMed ID: 22093120
[TBL] [Abstract][Full Text] [Related]
53. [Ambroxol. Prophylaxis and therapy of pulmonary complications. Symposium on the occasion of the 12th International Sylt Week on Anesthesiology. 9 September 1998].
Anaesthesist; 1998 Nov; 47(11 Suppl Prophylaxe):1-12. PubMed ID: 9884733
[No Abstract] [Full Text] [Related]
54. Rescue use of DNase in critical lung atelectasis and mucus retention in premature neonates.
El Hassan NO; Chess PR; Huysman MW; Merkus PJ; de Jongste JC
Pediatrics; 2001 Aug; 108(2):468-70. PubMed ID: 11483817
[TBL] [Abstract][Full Text] [Related]
55. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study.
Robinson M; Daviskas E; Eberl S; Baker J; Chan HK; Anderson SD; Bye PT
Eur Respir J; 1999 Sep; 14(3):678-85. PubMed ID: 10543292
[TBL] [Abstract][Full Text] [Related]
56. Inhaled mucoactive drugs for treating non-cystic fibrosis bronchiectasis in children.
Snijders D; Calgaro S; Bertozzi I; Quartesan S; Kozuh I; Lunardi F; Barbato A
Int J Immunopathol Pharmacol; 2013; 26(2):529-34. PubMed ID: 23755770
[TBL] [Abstract][Full Text] [Related]
57. The pharmacologic approach to airway clearance: mucoactive agents.
Rubin BK
Respir Care; 2002 Jul; 47(7):818-22. PubMed ID: 12088552
[TBL] [Abstract][Full Text] [Related]
58. Nebulised dornase alpha: adherence in adults with cystic fibrosis.
Burrows JA; Bunting JP; Masel PJ; Bell SC
J Cyst Fibros; 2002 Dec; 1(4):255-9. PubMed ID: 15463823
[TBL] [Abstract][Full Text] [Related]
59. Effect of a short course of rhDNase on cough and mucociliary clearance in patients with cystic fibrosis.
Robinson M; Hemming AL; Moriarty C; Eberl S; Bye PT
Pediatr Pulmonol; 2000 Jul; 30(1):16-24. PubMed ID: 10862158
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
